

## **Regina Hodits joins Wellington Partners as General Partner**

Munich, January 13, 2011. Dr. Regina Hodits (41) has joined Wellington Partners as General Partner. Alongside Wellington founder Rolf Dienst and further General Partners Prof. Erich Schlick, Dr. Rainer Strohmenger, Dr. Thomas Widmann, Harald Keller and Ernst Mannheimer, Dr. Regina Hodits – who holds a doctorate in biochemistry – will be driving the expansion of Wellington’s investment portfolio in the fields of therapeutics, diagnostics and medical technology. The Wellington Life Sciences portfolio currently consists of 14 companies, the majority of which are already revenue-generating, including publicly traded Evolva in Switzerland, mtm laboratories, invendo medical and immatics in Germany, Supersonic Imagine and implanet in France, and Oxford Immunotec in the UK.

Dr. Hodits, who has already been supporting the team in an advisory role since February 2010, notes: “During the last year, I learned to value the Wellington team even more. It is characterized by an in-depth understanding of medical needs, a wealth of experience in developing and launching new products, lots of financial and transaction expertise and an excellent worldwide network. I am looking forward to contributing to Wellington’s proven investment strategy of guiding European life sciences companies towards global success, and thus delivering superior returns to our investors.”

Dr. Regina Hodits has been active as a venture capital investor in life sciences for over 10 years, gaining experience from both early-stage and growth financing. Until January 2010, she headed Atlas Venture’s life sciences investment activities in Europe. In this capacity, she was the founding investor of successful start-ups like Bicycle Therapeutics, F-star and Jenavalve and served as a Board Member at Egalet, Novamed, Protaffin and U3 Pharma, which was acquired by Daiichi Sankyo Co., Ltd., in 2008. From 2000 to 2004 she worked at Apax Partners, where she was responsible for healthcare investments in Germany and played a major role in investments like Genmab, Silence Therapeutics and Wilex.

Wellington General Partner Dr. Rainer Strohmenger is excited about the collaboration: "With her experience, network and track record, Dr. Regina Hodits is the perfect addition to our team. She is joining Wellington just at the right time, as momentum and growth are picking up in the European life sciences sector. We see professionally managed companies with numerous highly promising development projects that are boldly taking advantage of the growth opportunities in the worldwide healthcare market. Our 20 years of experience make us the counterpart of choice in this environment, enabling our investors to strongly benefit from the upswing."

#### **About Wellington Partners**

Wellington Partners is one of the most successful pan-European venture capital firms. With some € 800 million under management and offices in London, Munich, Palo Alto and Zurich, the firm invests into companies throughout Europe that have the potential to become global leaders, in the areas of Digital Media, Technology and Life Sciences.

Since 1998, Wellington has invested in more than 100 companies, including publicly traded Actelion, Wavelight, Evolva and XING and successful privately held companies like Alando (acquired by eBay) and Grandis (acquired by Novartis). For more information please visit [www.wellington-partners.com](http://www.wellington-partners.com).

#### **Contact**

Wellington Partners  
Regina Hodits  
General Partner  
T: +49 89 2199 4125  
[hodits@wellington-partners.com](mailto:hodits@wellington-partners.com)

Wellington Partners  
Stefan Schwartz  
PR Advisor  
T: +49 89 2199 4129  
[schwartz@wellington-partners.com](mailto:schwartz@wellington-partners.com)